	US 12,404,330 B2
	Antibodies to ICOS
Aksana Labokha, Cambridge (GB); Nahida Parveen, Cambridge (GB); Jacob Galson, Cambridge (GB); Richard Charles Alfred Sainson, Cambridge (GB); and Stephen John Arkinstall, Cambridge, MA (US)
Assigned to KYMAB LIMITED, Cambridge (GB)
Appl. No. 16/955,197
Filed by KYMAB LIMITED, Cambridge (GB)
PCT Filed Dec. 19, 2018, PCT No. PCT/GB2018/053701 § 371(c)(1), (2) Date Jun. 18, 2020, PCT Pub. No. WO2019/122884, PCT Pub. Date Jun. 27, 2019.
Claims priority of application No. 1721338 (GB), filed on Dec. 19, 2017.
Prior Publication US 2020/0317786 A1, Oct. 8, 2020
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01)

CPC C07K 16/2818 (2013.01) [A61P 35/00 (2018.01); A61K 45/06 (2013.01); C07K 2317/565 (2013.01)]

16 Claims

1. An isolated antibody that binds the extracellular domain of human and mouse ICOS, wherein the antibody comprises a VH domain comprising a set of heavy chain complementarity determining regions (HCDRs) HCDR1, HCDR2 and HCDR3, and a VL domain comprising a set of light chain complementarity determining regions (LCDRs) LCDR1, LCDR2 and LCDR3, wherein the HCDRs and LCDRs have amino acid sequences as follows:

HCDR1 comprises an amino acid sequence identical to SEQ ID NO: 992 or SEQ ID NO: 995;

HCDR2 comprises an amino acid sequence identical to SEQ ID NO: 993 or SEQ ID NO: 996;

HCDR3 comprises an amino acid sequence identical to SEQ ID NO: 994 or SEQ ID NO: 997;

LCDR1 comprises an amino acid sequence identical to SEQ ID NO: 1000 or SEQ ID NO: 1003;

LCDR2 comprises an amino acid sequence identical to SEQ ID NO: 1001 or SEQ ID NO: 1004; and

LCDR3 comprises an amino acid sequence identical to SEQ ID NO: 1002.